[go: up one dir, main page]

FR2961695B1 - Utilisation de composes dans le traitement ou la prevention de troubles cutanes - Google Patents

Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Info

Publication number
FR2961695B1
FR2961695B1 FR1055245A FR1055245A FR2961695B1 FR 2961695 B1 FR2961695 B1 FR 2961695B1 FR 1055245 A FR1055245 A FR 1055245A FR 1055245 A FR1055245 A FR 1055245A FR 2961695 B1 FR2961695 B1 FR 2961695B1
Authority
FR
France
Prior art keywords
prevention
compounds
treatment
skin disorders
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1055245A
Other languages
English (en)
Other versions
FR2961695A1 (fr
Inventor
Jerome Aubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR1055245A priority Critical patent/FR2961695B1/fr
Priority to EP11729296.1A priority patent/EP2588092A1/fr
Priority to JP2013517284A priority patent/JP2013533870A/ja
Priority to US13/807,675 priority patent/US20130231393A1/en
Priority to PCT/EP2011/060953 priority patent/WO2012001076A1/fr
Priority to CA2801466A priority patent/CA2801466A1/fr
Publication of FR2961695A1 publication Critical patent/FR2961695A1/fr
Application granted granted Critical
Publication of FR2961695B1 publication Critical patent/FR2961695B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1055245A 2010-06-29 2010-06-29 Utilisation de composes dans le traitement ou la prevention de troubles cutanes Expired - Fee Related FR2961695B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1055245A FR2961695B1 (fr) 2010-06-29 2010-06-29 Utilisation de composes dans le traitement ou la prevention de troubles cutanes
EP11729296.1A EP2588092A1 (fr) 2010-06-29 2011-06-29 Utilisation de squaramide dans la prévention et/ou le traitement de la rosacée
JP2013517284A JP2013533870A (ja) 2010-06-29 2011-06-29 酒さの予防および／または治療におけるスクワラミドの使用
US13/807,675 US20130231393A1 (en) 2010-06-29 2011-06-29 Use of squaramide in the prevention and/or treatment of rosacea
PCT/EP2011/060953 WO2012001076A1 (fr) 2010-06-29 2011-06-29 Utilisation de squaramide dans la prévention et/ou le traitement de la rosacée
CA2801466A CA2801466A1 (fr) 2010-06-29 2011-06-29 Utilisation de squaramide dans la prevention et/ou le traitement de la rosacee

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055245A FR2961695B1 (fr) 2010-06-29 2010-06-29 Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Publications (2)

Publication Number Publication Date
FR2961695A1 FR2961695A1 (fr) 2011-12-30
FR2961695B1 true FR2961695B1 (fr) 2012-07-06

Family

ID=43432305

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1055245A Expired - Fee Related FR2961695B1 (fr) 2010-06-29 2010-06-29 Utilisation de composes dans le traitement ou la prevention de troubles cutanes

Country Status (6)

Country Link
US (1) US20130231393A1 (fr)
EP (1) EP2588092A1 (fr)
JP (1) JP2013533870A (fr)
CA (1) CA2801466A1 (fr)
FR (1) FR2961695B1 (fr)
WO (1) WO2012001076A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
EP3471731A1 (fr) 2016-06-16 2019-04-24 Almirall S.A. Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
WO2019136370A2 (fr) 2018-01-08 2019-07-11 Chemocentryx, Inc. Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2
CN116874466A (zh) 2018-09-21 2023-10-13 辉瑞公司 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1818325E (pt) * 2001-04-16 2010-05-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-di-substituídas como ligandos de receptor de quimoquina cxc
NZ535314A (en) * 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
ES2373947T3 (es) * 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
FR2866565A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un modulateur du il-8rb et/ou pac-1 pour le traitement de la rosacee
FR2866569B1 (fr) * 2004-02-20 2007-08-24 Galderma Res & Dev Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
JP2009542700A (ja) * 2006-07-07 2009-12-03 シェーリング コーポレイション Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン
CN101568777B (zh) 2006-12-26 2012-02-15 开利公司 带有排气至吸气旁路的脉宽调制
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
EP2135864A1 (fr) * 2008-06-16 2009-12-23 Faes Farma, S.A. Dérivés de 5-(4-methanesulfonyl-phenyl)-thiazole pour le traitement de maladies inflammatoires aiguës et chroniques
WO2010063802A1 (fr) * 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2

Also Published As

Publication number Publication date
WO2012001076A1 (fr) 2012-01-05
EP2588092A1 (fr) 2013-05-08
US20130231393A1 (en) 2013-09-05
CA2801466A1 (fr) 2012-01-05
FR2961695A1 (fr) 2011-12-30
JP2013533870A (ja) 2013-08-29

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
MY175950A (en) Heterocyclyl compounds as mek inhibitors
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
PH12016502355A1 (en) Pharmaceutical composition
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
NZ714963A (en) Compositions and methods for treating anemia
WO2014169094A3 (fr) Composés de liaison à nhe3 et procédés d'inhibition du transport de phosphate
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
WO2013028818A8 (fr) Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EA201600434A1 (ru) Применение производных бензимидазолпролина
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
ME02405B (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160229